MODIFICATION
66 -- Procurement of an Andrew 1000R XL Automated System
- Notice Date
- 5/8/2017
- Notice Type
- Modification/Amendment
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP72574-88
- Archive Date
- 6/7/2017
- Point of Contact
- Chad M. Shearer, Phone: 2402766801
- E-Mail Address
-
chad.shearer@nih.gov
(chad.shearer@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- General Information Short Title: Procurement of an Andrew 1000R XL Automated System Document Type: Presolicitation Notice Solicitation Number: N02CP72574-88 Posted Date: 5/8/17 Response Date: 5/23/17 Classification Code: 6640 - Laboratory Equipment and Supplies NAICS Code: 334516 - Analytical Laboratory Instrument Manufacturing (1,000 employees) Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E626, Bethesda, MD 20892, UNITED STATES. Description The National Cancer Institute (NCI), Cancer Epidemiology and Genetics (DCEG), plans to procure on a sole source basis purchase an automated pipetting system from Andrew Alliance USA Inc., 185 Dartmouth Street, Boston, MA 02116. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR Part 13.106-1(b)(1), using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 334516 and the business size standard is 1,000 employees. Only one (1) award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. Clinical Genetics Branch (CGB) investigators study individuals at high genetic risk of cancer in order to improve understanding of cancer etiology and to advance clinical care. This work is carried out through two major research approaches: familial studies and clinical genetics. CGB's research mission is to conduct multidisciplinary research to advance our understanding of the molecular pathogenesis of cancer and to translate this knowledge into effective clinical applications for cancer-prone individuals and families, and for individuals at increased risk of cancer from the general population. HPV testing alone or with cytology ("cotesting") is being introduced into primary screening. The multiplicity of new options creates confusion over how to best incorporate HPV testing. Because most HPV infections are harmless, additional triage tests must identify HPV-positive women at highest cancer risk and no best strategy has been identified. Within the Creation of a Biorepository for Discarded HPV Test Specimens study, the NCI will obtain and store aliquots of "discard" SurePath cytology and STM specimens. These specimens are termed "discard" because they are routinely discarded soon after processing in the laboratory that runs the cervical cancer screening tests. Over 550,000 aliquots will be taken from specimens for storage at the NCI Biorepository. This process is extremely labor-intensive and requires an automated system to increase productivity, maximize accuracy of specimen handling and minimize repetitive motion and risk of injury. An automated pipetting system is therefore required. The purpose of this acquisition is to purchase an automated pipetting system that will fit into an 18'' by 42'' by 18'' workspace and will work with original SurePath specimen tubes and vials as well as Qiagen HC2 vials and 1mL destination tubes. Considering these constraints, Andrews Alliance USA Inc. is the only contractor capable of meeting these requirements at this time according to NCI. This notice is not a request for competitive quotation. However, if any responsible source, especially small business, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the source can perform the requirement. Responses must be received in the contracting office by 8:00 AM EST, on May 23, 2017. All responses and questions must be in writing and faxed 240-276-5401 or emailed to Chad Shearer, Contract Specialist via electronic mail at chad.shearer@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the System for Award Management (SAM) through sam.gov. Reference: N02CP72574-88 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP72574-88/listing.html)
- Place of Performance
- Address: 9609 Medical Center Drive, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04499325-W 20170510/170508234318-1c603e883c1588b4aac4fdef17a3134b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |